Guardant Health announced that the Japanese Ministry of Health, Labour and Welfare has approved ENHERTU® (trastuzumab deruxtecan) for patients with HER2‑positive metastatic solid tumors, expanding the drug’s indication in the country.
The approval was supported by real‑world evidence generated by Guardant’s InfinityAI platform, an artificial‑intelligence and machine‑learning system that analyzes large, longitudinal datasets from Guardant’s clinical testing portfolio. InfinityAI provided supplemental evidence that helped demonstrate the drug’s efficacy in a biomarker‑defined population, complementing traditional clinical trial data and addressing gaps in patient representation.
For Guardant Health, the approval underscores the value of its data‑partner model and the growing importance of real‑world evidence in precision oncology. By enabling the generation of clinically meaningful insights from real‑world data, InfinityAI positions Guardant to support future regulatory submissions and broaden access to targeted therapies for patients who might otherwise be overlooked.
The approval also expands ENHERTU’s market access in Japan, where Daiichi Sankyo holds exclusive rights. The broader indication—encompassing all HER2‑positive solid tumors—builds on previous approvals for breast cancer (March 2020), gastric cancer (March 2026 second‑line therapy), and non‑small cell lung cancer (August 2023). This development signals a potential shift toward more inclusive biomarker‑driven approvals in the region.
Helmy Eltoukhy, Guardant Health chairman and co‑CEO, said: “This approval highlights the growing role of real‑world evidence in precision oncology and underscores the potential for new regulatory pathways in rare biomarker‑defined populations. InfinityAI allows us to generate clinically meaningful evidence from large‑scale, longitudinal data, helping to complement traditional trials and ultimately expand access to targeted therapies for patients who might otherwise be overlooked.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.